Home » Newsletters » BioWorld Science

BioWorld Science

May 21, 2001

View Archived Issues

Genzyme General reports Q1 2001 update

High exposure to ISIS-2302 associated with significant clinical response in Crohn's disease

Efficacy and safety results from phase II BXT-51072 trial discussed at DDW

Endovasc's Liprostin bypasses phase I/II and enters phase III for critical limb ischemia

Statistically significant reductions in BP reported for enalapril/nitrendipine

U.S. Army to test CT-3 in vivo

DDW news: selective adenosine A2A activation as a novel approach to IBD

Reversal of cardiomyopathy demonstrated in phase II trial of Replagal

High two-year survival rates obtained in stage III melanoma patients immunized with TriGem

OP-1 Implant receives second major approval

Replication-competent virus for i.v. administration tested in cancer patients

Company Profile: BioAxone Therapeutic

Yasmin receives FDA approval

Nabi begins trial to evaluate booster dose of Nabi StaphVAX in immunocompromised patients

GTI-2040 safe and well tolerated in initial dose-escalating trial

FDA approves clinical testing of ErythroMax cell-based oxygen therapeutic

ASCO presentation documents safety of TLK-286 over wide dose range, efficacy in advanced cancer

Effexor gains new FDA labeling approval regarding relapse

Abarelix as a new hormonal therapy for safely inducing medical castration in prostate cancer

Tachykinin antagonist/GABA analogue combinations useful for psychiatric disorders

Merck presents amine derivatives with PDE5-inhibitory effects

Subtype-selective NMDA receptor blockers and uses disclosed by Roche

Novel inhibitors of alphav integrin receptors discovered by Amgen team

Imidazole-based cytokine inhibitors designed at Merck & Co.

Novel treatments for CNS disorders emerge from R&D at Fujisawa

Pharmaceutically active compounds from Applied Research target JNK pathway

Boston Life Sciences' O-1369 shows promise in primates with Parkinson's disease

InterMune and MoliChem initiate pulmonary disease collaboration

Popular Stories

Today's news in brief
BioWorld
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 24, 2026